Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published March 10, 2023 | Submitted
Report Open

Index Cases First Identified by Nasal-Swab Rapid COVID-19 Tests Had More Transmission to Household Contacts Than Cases Identified by Other Test Types

Abstract

Importance. At-home rapid COVID-19 tests utilize nasal-swab specimens and require high viral loads to reliably give positive results. Longitudinal studies from the onset of infection have found infectious virus can present in oral specimens days before nasal. Detection and initiation of infection-control practices may therefore be delayed when nasal-swab rapid tests are used, resulting in greater exposure and transmission to contacts. Objective. We assessed whether index cases first identified by rapid nasal-swab COVID-19 tests had more transmission to household contacts than index cases who used other test types (tests with higher analytical sensitivity but longer turnaround times, and/or that utilize non-nasal specimen types). Design. In this observational cohort study, members of households with a recent COVID-19 case were screened for infection at least daily by RT-qPCR on one or more self-collected upper-respiratory specimen types. Participants reported demographic/medical information (including COVID-19 testing), symptom and exposure information, and household infection-control practices. A two-level random intercept model was used to assess the association between the infection outcome of household contacts and each covariable (household size, race/ethnicity, age, vaccination status, viral variant, infection-control practices, and whether a rapid nasal-swab test was used to initially identify the household index case). Setting. Southern California, September 2020—June 2021 and November 2021—March 2022. Participants. Cohort of 370 individuals from 85 households. Main Outcome(s) and Measure(s)Transmission was quantified by adjusted secondary attack rates (aSAR) and adjusted odds ratios (aOR). Results. An aSAR of 53.6% (95% CI 38.8–68.3%) was observed among households where the index case first tested positive by a rapid nasal-swab COVID-19 test, which was significantly higher than the aSAR for households where the index case utilized another test type (27.2% 95% CI 19.5– 35.0%,P=0.003 pairwise comparisons of predictive margins). We observed an aOR of 4.90 (95% CI 1.65–14.56) for transmission to household contacts when a nasal-swab rapid test was used to identify the index case, compared to other test types. Conclusions and Relevance. Use of nasal-swab rapid COVID-19 tests for initial detection of infection and initiation of infection control may not limit transmission as well as other test types. Key Points: Question: Does identification of index cases by rapid nasal-swab tests limit household transmission of SARS-CoV-2 as well as other test types? Finding. Significantly higher adjusted secondary attack rates and adjusted odds ratios for transmission were observed in households where the index case used a nasal rapid COVID-19 test for initial detection versus other test types. Meaning. The use of nasal-swab rapid COVID-19 tests for initial detection of infection and initiation of infection control may not limit transmission as well as other test types.

Additional Information

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. We thank the University of California, Los Angeles, Office of Advanced Research Computing, Statistical Methods and Data Analytics Group for recommendations on statistical methodology and implementation, and Dr. Andy Lin for guidance designing the analysis and feedback on the manuscript. This study is based on research funded in part by the Bill & Melinda Gates Foundation (INV-023124). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. This study was also funded in part by grants from the Ronald and Maxine Linde Center for New Initiatives at the California Institute of Technology (to RFI), a grant from the Jacobs Institute for Molecular Engineering for Medicine at the California Institute of Technology (to RFI), a DGSOM Geffen Fellowship at the University of California, Los Angeles (to AVW), and the John Stauffer Charitable Trust SURF Fellowship at the California Institute of Technology (to JJ). DATA SHARING STATEMENT. Raw data is available at CaltechDATA: https://doi.org/10.22002/csh5w-rf132. Competing Interest Statement. R.F.I. is a cofounder, consultant, and a director and has stock ownership of Talis Biomedical Corp. All other co-authors report no competing interests.

Attached Files

Submitted - 2023.03.09.23286855v1.full.pdf

Files

2023.03.09.23286855v1.full.pdf
Files (3.3 MB)
Name Size Download all
md5:f77ac80c6ad057bc26677b78c257e2d0
3.3 MB Preview Download

Additional details

Created:
August 20, 2023
Modified:
December 22, 2023